AVROBIO Inc. is a clinical-stage biopharmaceutical company developing lentiviral-based gene therapies for rare genetic diseases and cancer, using ex vivo approaches to modify patients' hematopoietic stem cells (HSCs) with a functional gene copy for durable, one-time treatment.[1][2][3] It targets conditions like Gaucher disease, Hunter syndrome, and Pompe disease via its proprietary plato® platform, which emphasizes scalable manufacturing for global commercialization, serving patients with unmet needs in genetic disorders by addressing root causes at the cellular level.[1][3] The company, headquartered in Cambridge, MA, focuses on transformative, single-dose therapies but underwent a 2024 merger with Tectonic Therapeutic, shifting resources with a strengthened cash position of ~$165M to fund operations through mid-2027 amid ongoing R&D.[4]
AVROBIO was founded by industry leaders with expertise in cell and gene therapy, driven by the convergence of these fields to accelerate breakthroughs in treating debilitating diseases through efficient gene delivery systems.[1] The idea emerged from scientific founders' years of intensive research, advancing innovative lentiviral technologies to human clinical stages, with early programs targeting rare diseases like Gaucher and Hunter syndrome.[1][3] Headquartered in Cambridge, MA, the company built traction through its first-in-class pipeline and proprietary plato® platform, culminating in the pivotal 2024 merger with Tectonic Therapeutic, which combined platforms, restructured the board, and added $130.7M in private placement funding.[4]
AVROBIO rides the gene therapy wave, fueled by advances in genetic engineering and CRISPR-like tools, timing into a biotech boom where one-time cures disrupt chronic treatments for rare diseases amid rising regulatory approvals.[2][4] Market forces like increasing investment in cell/gene modalities (~$165M post-merger cash) and partnerships with research institutions favor its scalable plato® platform, addressing gaps in cancer and orphan diseases where traditional pharma struggles.[2][3][4] It influences the ecosystem by pioneering efficient lentiviral vectors, pushing automation in manufacturing, and merging with immunology innovators like Tectonic, enhancing governance and R&D in a high-scrutiny sector.[4][5]
Post-2024 merger, AVROBIO's priorities likely pivot toward Tectonic's novel science while leveraging gene therapy assets, with cash runway to mid-2027 funding clinical advances in rare diseases and potential oncology expansions.[4] Trends like AI-driven automation in biomanufacturing and regulatory tailwinds for gene therapies will shape progress, potentially evolving its role from pure-play gene therapy to a hybrid platform leader influencing scalable cures.[5] As a catalyst for single-dose transformations, its trajectory hinges on trial data and partnerships, positioning it to redefine genetic medicine accessibility.[1]
Avrobio has raised $85.0M in total across 2 funding rounds.
Avrobio's investors include Atlas Venture, Endeavor Venture Funds, Ben Robbins, Hatteras Venture Partners.
Avrobio has raised $85.0M across 2 funding rounds. Most recently, it raised $60.0M Series B in January 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2018 | $60.0M Series B | Atlas Venture, Endeavor Venture Funds, Ben Robbins, Hatteras Venture Partners | |
| Aug 1, 2016 | $25.0M Series A | Atlas Venture, Endeavor Venture Funds, Ben Robbins, Hatteras Venture Partners |
